A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5 Mcg, Vilanterol 25 Mcg, and Umeclidinium/Vilanterol 62.5/25 Mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 25 Jul 2023
At a glance
- Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary) ; Vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Jan 2016 Results of pooled analysis of two identical phase III studies published in the Respiratory Medicine.
- 24 Dec 2013 New trial record